Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ProtheraCytes
- Development stage
- Unknown
- Lead developer
- CellProthera
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intracoronary
01
Overview
ProtheraCytes is an autologous cell therapy product consisting of freshly prepared CD34+ stem cells derived from the peripheral blood of patients after mobilization from the bone marrow. The therapy is designed for regeneration and repair of damaged tissues, particularly cardiac tissue following acute myocardial infarction (AMI). The CD34+ cells are expanded, purified, and formulated into a fresh cell suspension for injection. Mechanistically, ProtheraCytes promote revascularization, regulate inflammation and apoptosis, secrete vascular endothelial growth factor (VEGF), release exosomes containing proangiogenic and antiapoptotic microRNAs, and support cardiomyocyte regeneration. Clinical studies have shown promising results in improving left ventricular function post-AMI. Developed by CellProthera, the therapy is currently in Phase II clinical development for myocardial infarction and has also been investigated preclinically for ischemic stroke.
- Brand names
- ProtheraCytes
- Other names
- ProtheraCytes
Beyond the preview
Go deeper on ProtheraCytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProtheraCytes.